This Medical-Devices Stock Is Soaring. It Could Be in Line for an Acquisition. -- Barrons.com

Dow Jones

02/17

By Adam Clark

Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher.

Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday.

Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday.

Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts.

In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close.

Danaher is a maker of tools and equipment for the biotechnology, life sciences, and diagnostic industries. The company was a Barron's stock pick in January, arguing that the company had the financial firepower to restart mergers-and-acquisitions activity which could boost growth.

Danaher shares were down 4.6% in premarket trading. The stock had dropped 7.1% this year so far through to Friday's close.

Write to Adam Clark at adam.clark@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 17, 2026 05:39 ET (10:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612102455"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612102455\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612102455?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612102455","market":"other","top_or_hot":-1,"title":"This Medical-Devices Stock Is Soaring. It Could Be in Line for an Acquisition. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Adam Clark \n</p>\n<p>\n  Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher. \n</p>\n<p>\n  Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday. \n</p>\n<p>\n  Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday. \n</p>\n<p>\n  Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts. \n</p>\n<p>\n  In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close. \n</p>\n<p>\n  Danaher is a maker of tools and equipment for the biotechnology, life sciences, and diagnostic industries. The company was a Barron's stock pick in January, arguing that the company had the financial firepower to restart mergers-and-acquisitions activity which could boost growth. \n</p>\n<p>\n  Danaher shares were down 4.6% in premarket trading. The stock had dropped 7.1% this year so far through to Friday's close. \n</p>\n<p>\n  Write to Adam Clark at adam.clark@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 17, 2026 05:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Medical-Devices Stock Is Soaring. It Could Be in Line for an Acquisition. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Medical-Devices Stock Is Soaring. It Could Be in Line for an Acquisition. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-17 18:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Adam Clark \n</p>\n<p>\n  Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher. \n</p>\n<p>\n  Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday. \n</p>\n<p>\n  Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday. \n</p>\n<p>\n  Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts. \n</p>\n<p>\n  In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close. \n</p>\n<p>\n  Danaher is a maker of tools and equipment for the biotechnology, life sciences, and diagnostic industries. The company was a Barron's stock pick in January, arguing that the company had the financial firepower to restart mergers-and-acquisitions activity which could boost growth. \n</p>\n<p>\n  Danaher shares were down 4.6% in premarket trading. The stock had dropped 7.1% this year so far through to Friday's close. \n</p>\n<p>\n  Write to Adam Clark at adam.clark@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 17, 2026 05:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561818.USD","symbol_name":"安联收益及增长平衡基金Cl AM DIS","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612102455","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612102455","pubTimestamp":1771324740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher.Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday.Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday.Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts.In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close.Danaher is a maker of tools and equipment for the biotechnology, life sciences, a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4581":"高盛持仓","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","MASI":"麦斯莫医疗","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","DHR":"丹纳赫","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4504":"桥水持仓","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC"},"translate_title":"这只医疗器械股票正在飙升。它可能会被收购。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MASI":0.9,"DHR":0.9},"content_text":"By Adam Clark \n\n\n  Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher. \n\n\n  Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday. \n\n\n  Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday. \n\n\n  Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts. \n\n\n  In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close. \n\n\n  Danaher is a maker of tools and equipment for the biotechnology, life sciences, and diagnostic industries. The company was a Barron's stock pick in January, arguing that the company had the financial firepower to restart mergers-and-acquisitions activity which could boost growth. \n\n\n  Danaher shares were down 4.6% in premarket trading. The stock had dropped 7.1% this year so far through to Friday's close. \n\n\n  Write to Adam Clark at adam.clark@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 05:39 ET (10:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}